使用水痘疫苗预防老年人带状疱疹。

Use of varicella vaccines to prevent herpes zoster in older individuals.

作者信息

Levin M J

机构信息

Department of Pediatrics, University of Colorado School of Medicine, Denver 80262, USA.

出版信息

Arch Virol Suppl. 2001(17):151-60. doi: 10.1007/978-3-7091-6259-0_16.

DOI:10.1007/978-3-7091-6259-0_16

PMID:11339544

Abstract

It is likely that the frequency and severity of herpes zoster in older people is the result of an age-related decline in varicella-zoster virus-specific T-cell mediated immunity. Numerous trials of vaccines to boost these responses have demonstrated their safety and immunogenicity. Both live attenuated and inactivated vaccines have been studied. Persistence of booster responses is dose-related, and the half-life of some boosted measures of T-cell mediated immunity exceeds 5 years. Although these trials have been hampered by uncertainty about the critical immune responses to evaluate, the stage is set for a double-blind, placebo-controlled trial of sufficient size to determine efficacy. Such a trial is now underway.

摘要

老年人带状疱疹的发病率和严重程度可能是水痘-带状疱疹病毒特异性T细胞介导的免疫力随年龄下降的结果。许多旨在增强这些反应的疫苗试验已证明了其安全性和免疫原性。减毒活疫苗和灭活疫苗都已得到研究。增强反应的持续性与剂量相关，一些T细胞介导免疫的增强指标的半衰期超过5年。尽管这些试验因评估关键免疫反应存在不确定性而受到阻碍，但开展一项足够规模的双盲、安慰剂对照试验以确定疗效的条件已经具备。这样一项试验正在进行中。